Vasomune Therapeutics, Inc. will present the therapeutic capabilities of its investigational drug candidate Pegevongitide, also known as AV-001, at the 2026 NATO Support and Procurement Agency conference on chemical, biological, radiological and nuclear threats. The meeting is scheduled for September 28 and 29, 2026, at the agency’s headquarters in Capellen, Luxembourg, where Vasomune Chief Executive Officer Brian Jahns is expected to discuss the programme’s potential relevance to military casualty care and civilian emergency preparedness.
The invitation gives the privately held Canadian biotechnology company access to an audience involved in defence preparedness, medical countermeasures and multinational procurement. It does not, however, represent a NATO endorsement, procurement decision, development contract or confirmation that Pegevongitide is effective against injuries caused by chemical, biological, radiological or nuclear agents.
What Vasomune is presenting is primarily a mechanistic and development-stage argument. The company believes that stabilising the vascular endothelium could address a biological process shared by several critical illnesses and injuries, including acute respiratory distress syndrome, severe burns, haemorrhagic shock and some forms of trauma. Whether that common mechanism can support a broadly useful medical countermeasure will depend on evidence that remains substantially less mature than the strategic positioning.
Why does a NATO CBRN presentation matter without new Pegevongitide clinical data?
The NATO Support and Procurement Agency serves as the alliance’s lead organisation for multinational acquisition, support and sustainment. Its involvement in a conference can therefore provide companies with visibility among governments, defence medical organisations, scientists and procurement specialists, but participation should not be confused with entering NATO’s supply system or securing an acquisition pathway.
For Vasomune, the presentation advances a dual-use development narrative that has become increasingly visible during 2026. The company has already announced a Pegevongitide presentation at the Military Health System Research Symposium in August, where its scientific leadership plans to discuss vascular leak in blast trauma, burns, haemorrhagic shock and infection-associated respiratory injury. The NATO appearance extends that engagement from a scientific military-health setting into a forum more directly associated with alliance preparedness and support capabilities.
The latest announcement does not contain additional animal results, human efficacy findings or CBRN-specific studies. It instead positions endothelial barrier failure as a common downstream pathology that may be relevant across otherwise different casualty scenarios.
That distinction is important. A treatment might act on a shared biological response without necessarily being equally effective across blast injury, inhalational exposure, radiation injury, infection and severe burns. The timing of vascular damage, accompanying organ injuries, supportive-care requirements and therapeutic window could differ sharply across those settings.
Pegevongitide’s NATO presentation is therefore best interpreted as an opportunity for scientific and strategic engagement. It could help Vasomune identify development partners, government research requirements or future countermeasure studies, but it does not independently reduce the programme’s clinical risk.
How is Pegevongitide designed to control vascular leak through the Tie2 pathway?
Pegevongitide is a synthetic PEGylated peptide intended to activate Tie2, a receptor found predominantly on vascular endothelial cells. Vasomune describes the candidate as a first-in-class Tie2 agonist designed to strengthen endothelial junctions, promote vascular stability and limit the escape of fluid and proteins from the circulation into surrounding tissues.
Under healthy conditions, the endothelial lining regulates the movement of fluid, proteins, inflammatory cells and signalling molecules between the bloodstream and tissues. During severe infection, systemic inflammation, shock or traumatic injury, this barrier can become destabilised. The resulting leakage may contribute to tissue oedema, impaired oxygen delivery, reduced organ perfusion and progressive organ dysfunction.
The Tie2 and angiopoietin signalling system has been studied extensively in critical illness, including sepsis and acute respiratory distress syndrome. Scientific reviews have identified the pathway as a plausible regulator of vascular integrity, but they also underscore the gap between identifying an important biological pathway and demonstrating that pharmacological activation produces meaningful outcomes in heterogeneous critically ill patients.
This host-directed approach gives Pegevongitide theoretical breadth. Unlike a treatment directed against one infectious organism or toxin, an endothelial stabiliser might retain relevance across several causes of vascular injury.
Breadth, however, can become a development challenge. A candidate intended for multiple indications must establish appropriate dosing, timing, endpoints and patient selection in each clinical context. Evidence from pneumonia-associated respiratory failure cannot automatically establish benefit in haemorrhagic shock, severe burns or CBRN exposure.
How mature is Pegevongitide’s human evidence in pneumonia-associated ARDS?
Pegevongitide has completed a randomised, double-blind, placebo-controlled Phase 1 study in 48 healthy participants. Vasomune has reported that the candidate was generally well tolerated across the tested single and multiple ascending doses, with a pharmacokinetic profile considered suitable for once-daily administration and pharmacodynamic evidence of Tie2 activation. These findings were subsequently presented at an American Thoracic Society meeting, but Phase 1 tolerability in healthy volunteers cannot establish efficacy in critically ill patients.
The principal human efficacy programme is AV001-004, a Phase 2a study registered as NCT05123755. The trial is designed to enrol approximately 120 adults hospitalised with viral or bacterial pneumonia and respiratory compromise requiring supplemental oxygen. Participants are randomised equally to intravenous Pegevongitide or placebo alongside standard care, with sequential dose cohorts ranging from 12.5 to 56 micrograms per kilogram per day and a later cohort selected using emerging safety and efficacy information.
The trial’s primary outcome is safety and tolerability through day 60, including serious adverse events and treatment-emergent adverse events. Efficacy measures are secondary or exploratory and include improvement on a clinical progression scale, progression to respiratory failure, mechanical ventilation, survival, hospital discharge, renal outcomes and biomarkers of Tie2 engagement.
That structure makes AV001-004 an early signal-generating study rather than a definitive efficacy trial. Even favourable secondary outcomes would need to be interpreted alongside sample size, dose-cohort structure, missing data, baseline disease severity and the diversity of viral and bacterial causes represented in the study.
The clinical trial registry was last updated on February 27, 2026, and continued to list the trial as recruiting. It estimated primary completion in May 2026 and study completion in June 2026, but no results were posted as of July 27. The passage of those estimated dates does not prove a delay because registry timelines can lag operational developments, although it leaves the programme without a publicly disclosed Phase 2 efficacy dataset at the time of the NATO announcement.
An independent monitoring board previously recommended that the study continue and progress into its high-dose cohort. That recommendation indicates that the board did not identify a disclosed reason to stop escalation at that review, but it should not be interpreted as evidence that Pegevongitide is effective.
What do the severe-burn and haemodialysis programmes add to the dual-use argument?
The United States Food and Drug Administration granted Fast Track designation to Pegevongitide in 2024 for the prevention or treatment of moderate-to-severe acute respiratory distress syndrome in patients hospitalised with viral or bacterial respiratory infections. Fast Track status can facilitate regulatory interaction and development, but it is not marketing approval and does not establish clinical benefit.
In March 2026, the agency cleared a separate Investigational New Drug application allowing Vasomune and co-development partner AnGes, Inc. (Tokyo: 4563) to initiate clinical evaluation of Pegevongitide in the acute resuscitation of severely burned patients. The programme is based on the hypothesis that endothelial stabilisation could reduce the extensive fluid movement, oedema and haemodynamic instability that complicate severe burn resuscitation.
That regulatory clearance expands the candidate’s permitted clinical-development scope. It does not mean that Pegevongitide has been cleared or approved as a burn treatment, nor does it show that the candidate reduces fluid requirements, organ failure, intensive-care stays or mortality. Those questions require an appropriately designed clinical trial.
Vasomune has also moved Pegevongitide into an investigator-initiated haemodialysis study in Canada. The first participant was dosed in March 2026 in a programme examining whether the candidate can reduce dialysis-associated cerebral injury by protecting the brain’s microvasculature. The study incorporates neuroimaging, cognitive assessments and biomarker evaluation, with any positive findings expected to inform a larger confirmatory trial.
The haemodialysis programme is clinically distinct from CBRN preparedness, but it supports Vasomune’s broader platform thesis that Tie2 activation may have applications in different forms of vascular destabilisation. At the same time, operating several early-stage programmes can increase capital, manufacturing and clinical-execution demands for a small private biotechnology company.
What would Pegevongitide need to become a credible medical countermeasure?
A medical countermeasure intended for defence or mass-casualty use must meet requirements that extend beyond conventional proof of biological activity. Authorities may need evidence regarding treatment timing, effectiveness after delayed administration, compatibility with standard resuscitation, ease of use, storage stability, manufacturing capacity and performance across relevant injury models.
Pegevongitide is administered as an intravenous injection in its pneumonia Phase 2a protocol, with treatment given daily until the earlier of day 28 or hospital discharge. The protocol specifies a bolus injection lasting less than 60 seconds, which may be operationally simpler than a prolonged infusion, but it still requires vascular access, trained personnel and repeated drug availability.
The eventual dosing regimen for burns, trauma or CBRN-related injury could be different. Nevertheless, the existing clinical design highlights questions that defence stakeholders are likely to examine. A treatment requiring prolonged hospital administration may occupy a different preparedness role from a field-deployable product that can be stored, transported and administered rapidly in an austere environment.
The company would also need to define which CBRN scenarios are biologically and clinically appropriate. The term covers highly diverse exposures, and vascular leak may be central in some injuries but secondary or less modifiable in others. A broad mechanistic claim will eventually need to be translated into specific indications, treatment windows and measurable outcomes.
Animal-model data can support countermeasure development, particularly where human exposure trials are unethical, but relevance depends on the quality of the model and the regulatory pathway. The current announcement does not identify a completed chemical-agent, radiation or combined-injury study that establishes Pegevongitide’s effectiveness as a CBRN countermeasure.
Can strategic defence interest improve Pegevongitide’s commercial prospects?
Pegevongitide has already received support from the United States Department of Defense through Congressionally Directed Medical Research Programs awards that helped advance the candidate into the clinic and supported the Phase 2a pneumonia study. This funding history provides a foundation for Vasomune’s military-health engagement and shows that government agencies have previously considered the programme scientifically relevant.
A successful dual-use strategy could give Vasomune access to non-dilutive research funding, specialised clinical networks, development partnerships and potential government procurement channels. It could also diversify the programme beyond the conventional commercial market for acute respiratory distress syndrome, where trials are difficult because patients are heterogeneous, severely ill and treated alongside complex supportive-care protocols.
Those opportunities remain prospective. The NATO conference announcement contains no new grant, contract, stockpiling agreement, purchase commitment or disclosed commercial value. Vasomune is privately held, while AnGes is publicly traded, but the companies announced no change to their co-development economics in connection with the presentation.
The next meaningful de-risking event will not be another conference invitation. It will be evidence showing whether Pegevongitide can safely produce clinically relevant improvements in a defined patient population.
Results from AV001-004, details of the severe-burn clinical protocol and any CBRN-specific development programme will therefore carry considerably more weight than the strategic visibility generated in Luxembourg. NATO’s audience may help Vasomune refine the destination, but Pegevongitide’s data must still prove that the therapeutic can complete the journey.
